JP2018523689A5 - - Google Patents

Download PDF

Info

Publication number
JP2018523689A5
JP2018523689A5 JP2018508757A JP2018508757A JP2018523689A5 JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5 JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018508757 A JP2018508757 A JP 2018508757A JP 2018523689 A5 JP2018523689 A5 JP 2018523689A5
Authority
JP
Japan
Prior art keywords
combination
pharmaceutical composition
kit
composition according
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2018508757A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018523689A (ja
Filing date
Publication date
Priority claimed from GBGB1514760.6A external-priority patent/GB201514760D0/en
Application filed filed Critical
Publication of JP2018523689A publication Critical patent/JP2018523689A/ja
Publication of JP2018523689A5 publication Critical patent/JP2018523689A5/ja
Withdrawn legal-status Critical Current

Links

JP2018508757A 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物 Withdrawn JP2018523689A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1514760.6 2015-08-19
GBGB1514760.6A GB201514760D0 (en) 2015-08-19 2015-08-19 Compounds and method of use
PCT/GB2016/052575 WO2017029517A1 (en) 2015-08-19 2016-08-19 Compositions comprising phosphoinositide 3-kinase inhibitors and a second antiproliferative agent

Publications (2)

Publication Number Publication Date
JP2018523689A JP2018523689A (ja) 2018-08-23
JP2018523689A5 true JP2018523689A5 (cg-RX-API-DMAC7.html) 2019-07-25

Family

ID=54258859

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018508757A Withdrawn JP2018523689A (ja) 2015-08-19 2016-08-19 ホスホイノシチド３−キナーゼ阻害剤および第二の抗増殖剤を含む組成物

Country Status (22)

Country Link
US (3) US10668077B2 (cg-RX-API-DMAC7.html)
EP (1) EP3337477B1 (cg-RX-API-DMAC7.html)
JP (1) JP2018523689A (cg-RX-API-DMAC7.html)
KR (1) KR20180064387A (cg-RX-API-DMAC7.html)
CN (2) CN108348505B (cg-RX-API-DMAC7.html)
AU (1) AU2016307885B2 (cg-RX-API-DMAC7.html)
CA (1) CA2995898A1 (cg-RX-API-DMAC7.html)
DK (1) DK3337477T3 (cg-RX-API-DMAC7.html)
ES (1) ES2939815T3 (cg-RX-API-DMAC7.html)
FI (1) FI3337477T3 (cg-RX-API-DMAC7.html)
GB (1) GB201514760D0 (cg-RX-API-DMAC7.html)
HR (1) HRP20230376T1 (cg-RX-API-DMAC7.html)
HU (1) HUE061615T2 (cg-RX-API-DMAC7.html)
IL (1) IL257499A (cg-RX-API-DMAC7.html)
LT (1) LT3337477T (cg-RX-API-DMAC7.html)
MX (1) MX2018001926A (cg-RX-API-DMAC7.html)
PL (1) PL3337477T3 (cg-RX-API-DMAC7.html)
PT (1) PT3337477T (cg-RX-API-DMAC7.html)
RS (1) RS64095B1 (cg-RX-API-DMAC7.html)
SI (1) SI3337477T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202300063T1 (cg-RX-API-DMAC7.html)
WO (1) WO2017029517A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2467387B1 (en) 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
GB201402431D0 (en) 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
US10722527B2 (en) 2015-04-10 2020-07-28 Capsugel Belgium Nv Abiraterone acetate lipid formulations
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
SG11202102343QA (en) * 2018-09-11 2021-04-29 Curis Inc Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
US20220008409A1 (en) * 2018-09-18 2022-01-13 Kabushiki Kaisha Yakult Honsha Cancer combination therapy using quinoline carboxamide derivative
HUE067967T2 (hu) * 2019-02-27 2024-12-28 Astrazeneca Ab Szarakatinib idiopátiás tüdõfibrózis kezelésében történõ alkalmazásra
CN111904958B (zh) * 2019-05-09 2022-09-13 浙江大学 Umi-77作为线粒体自噬诱导剂在制备治疗炎症及神经退行性疾病药物中的应用
GB201909468D0 (en) * 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer
WO2022105836A1 (en) * 2020-11-19 2022-05-27 Guangzhou Healthquest Pharma Co., Ltd. Combination therapies for treating cancer

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1445742A1 (de) 1963-11-06 1968-12-19 Bayer Ag Verfahren zur Herstellung von 2-Stellung substituierten Benzoxazinonen
US4017500A (en) 1973-07-16 1977-04-12 Schering Corporation Certain 8-amino-1,7-naphthyridines
BE786081A (fr) * 1971-07-13 1973-01-10 Uniroyal Sa Appareil et procede pour maintenir les tringles des bourrelets de pneu
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
CN1250294A (zh) * 1999-07-27 2000-04-12 邮电部武汉邮电科学研究院 以太网与同步数字体系或同步光网络融合的适配方法
HK1044277B (en) 1999-08-03 2014-02-28 Icos Corporation Pharmaceutical formulation comprising a beta-carboline and its use for treating sexual dysfunction
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1296975A1 (en) 2000-06-30 2003-04-02 Sugen, Inc. 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors
US6905669B2 (en) 2001-04-24 2005-06-14 Supergen, Inc. Compositions and methods for reestablishing gene transcription through inhibition of DNA methylation and histone deacetylase
EP2277867B1 (en) 2002-07-15 2012-12-05 Symphony Evolution, Inc. Compounds, pharmaceutical compositions thereof and their use in treating cancer
FR2846657B1 (fr) 2002-11-05 2004-12-24 Servier Lab Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
JP4912145B2 (ja) 2004-02-26 2012-04-11 あすか製薬株式会社 ピリミジン誘導体
EP1755609A1 (en) 2004-05-25 2007-02-28 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic cells
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
CA2609126A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
TW200738709A (en) 2006-01-19 2007-10-16 Osi Pharm Inc Fused heterobicyclic kinase inhibitors
JP5302186B2 (ja) 2006-04-26 2013-10-02 エフ．ホフマン−ラ ロシュ アーゲー Ｐｉ３ｋ阻害剤としてのピリミジン誘導体
WO2007127183A1 (en) 2006-04-26 2007-11-08 Genentech, Inc. Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
ATE510840T1 (de) 2006-06-26 2011-06-15 Ucb Pharma Sa Kondensierte thiazol-derivate als kinasehemmer
CN101501035B (zh) * 2006-08-08 2013-01-23 中外制药株式会社 作为pi3k抑制剂的嘧啶衍生物及其用途
NZ576997A (en) 2006-11-13 2012-02-24 Icos Corp Thienopyrimidinones for treatment of inflammatory disorders and cancers
AU2007334343A1 (en) 2006-12-15 2008-06-26 Ordway Research Institute, Inc. Treatments of therapy-resistant diseases comprising drug combinations
NZ578744A (en) 2007-01-31 2012-02-24 Vertex Pharma 2-aminopyridine derivatives useful as kinase inhibitors
US20100063032A1 (en) 2007-03-28 2010-03-11 Debenham John S Substituted pyrido[2,3-d]pyrimidine derivatives as cannabinoid-1 receptor modulators
WO2008150827A1 (en) 2007-05-29 2008-12-11 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
GB0710528D0 (en) 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
JP5658565B2 (ja) * 2007-09-12 2015-01-28 ジェネンテック， インコーポレイテッド ホスホイノシチド３−キナーゼ阻害剤化合物と化学療法剤との組合せ、および使用方法
EP2324022A1 (de) 2008-08-05 2011-05-25 Boehringer Ingelheim International GmbH Substituierte naphthyridine und ihre verwendung als arzneimittel
AU2009299894A1 (en) 2008-10-03 2010-04-08 Merck Serono S.A. 4 -morpholino-pyrido [3, 2 -d] pyrimidines active on Pi3k
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
EP2459543B1 (en) 2009-07-29 2017-08-30 Karus Therapeutics Limited Benzo[e][1,3]oxazin-4-one derivatives as phosphoinositide 3-kinase inhibitors
EP2467387B1 (en) * 2009-08-20 2015-01-07 Karus Therapeutics Limited Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors.
WO2011079231A1 (en) 2009-12-23 2011-06-30 Gatekeeper Pharmaceutical, Inc. Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
GB201007347D0 (en) 2010-04-30 2010-06-16 Karus Therapeutics Ltd Compounds
CN101849934B (zh) * 2010-05-25 2011-11-09 苏州大学 一种磷脂酰肌醇-3-激酶抑制剂及其应用
EP2518070A1 (en) 2011-04-29 2012-10-31 Almirall, S.A. Pyrrolotriazinone derivatives as PI3K inhibitors
CN105198862B (zh) 2011-07-27 2018-01-23 阿斯利康(瑞典)有限公司 取代的n‑(4‑氟‑2‑甲氧基‑5‑硝基苯基)嘧啶‑2‑胺化合物及其盐
WO2013017480A1 (en) 2011-07-29 2013-02-07 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as jak inhibitors
GB201204125D0 (en) 2012-03-08 2012-04-25 Karus Therapeutics Ltd Compounds
EP3181564B1 (en) 2012-11-20 2019-09-18 H. Hoffnabb-La Roche Ag Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
PT2994465T (pt) 2013-05-10 2018-10-25 Karus Therapeutics Ltd Novos inibidores de histona desacetilase
DK3003309T3 (da) * 2013-05-30 2020-12-14 Infinity Pharmaceuticals Inc Behandling af cancer med PI3-kinase-isoform modulatorer
WO2014210354A1 (en) 2013-06-28 2014-12-31 Genentech, Inc. Azaindazole compounds as inhibitors of t790m containing egfr mutants
JP6626437B2 (ja) 2013-10-08 2019-12-25 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤とＨｅｒ２阻害剤またはＰＩ３Ｋ阻害剤のいずれかの組み合わせ
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
GB201321728D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321738D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic Agents
GB201321730D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201321729D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
GB201402431D0 (en) * 2014-02-12 2014-03-26 Karus Therapeutics Ltd Compounds
MA40933A (fr) 2014-11-11 2017-09-19 Piqur Therapeutics Ag Difluorométhyl-aminopyridines et difluorométhyl-aminopyrimidines
GB201514758D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Formulation
GB201514756D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compound and method of use
GB201514760D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds and method of use
GB201514754D0 (en) * 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201514751D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
GB201909468D0 (en) 2019-07-01 2019-08-14 Karus Therapeutics Ltd Compounds for treating cancer

Similar Documents

Publication Publication Date Title
JP2018523689A5 (cg-RX-API-DMAC7.html)
CN102105152B (zh) 包含cdks抑制剂和抗肿瘤剂的治疗组合
CN111886006B (zh) 治疗肥大细胞增多症的组合疗法
US9937174B2 (en) Combinations of histone deacetylase inhibitors and bendamustine
EP4171548A1 (en) Combination therapy for treatment of cancer
US20170157134A1 (en) Combination therapy
FI3849534T3 (fi) Yhdistelmähoidot
JP5666910B2 (ja) 認知機能障害を治療するためのキット、組成物、製品もしくは医薬
JP2013528600A5 (cg-RX-API-DMAC7.html)
ES2698363T3 (es) Composiciones de oxprenolol para tratar el cáncer
SE9901573D0 (sv) New compounds
JP5440985B2 (ja) メラノーマの治療
JP2015522592A5 (cg-RX-API-DMAC7.html)
JPWO2022250170A5 (cg-RX-API-DMAC7.html)
EP4591940A3 (en) Deoxy- cytidine derivatives for use in cancer therapies
JP2010514734A (ja) 腸障害の治療のためのイソソルビドモノニトレート誘導体
EP2538935B1 (en) Suppression of cancer growth and metastasis using nordihydroguaiaretic acid derivatives with 7-hydroxystaurosporine
JP2016538295A5 (cg-RX-API-DMAC7.html)
Kawahara et al. Caffeine dose-dependently potentiates the antitumor effect of cisplatin on osteosarcomas
US20230060792A1 (en) Targeting Mcl-1 to Enhance DNA Replication Stress Sensitivity for Cancer Therapy
CN101605541A (zh) 有效治疗化疗药物引起的周围神经毒性的吡咯并[1,2-a]咪唑二酮
RU2341260C2 (ru) Комбинации, включающие производные эпотилона и алкилирующие агенты
US9907797B2 (en) Combination therapies for overcoming resistance to mitotic agents during chemotherapy
CN110891574A (zh) 用于预防和/或治疗肝细胞癌的美格列明
WO2025202854A1 (en) Cdk4 inhibitors and combinations with cdk2 inhibitors or further agents for use in the treatment of cancer